Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer

Activating mutations in the EGF receptor (EGFR) are associated with clinical responsiveness to EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib. However, resistance eventually arises, often due to a second EGFR mutation, most commonly T790M. Through a genome-wide siRNA screen...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: de Bruin, Elza C., Cowell, Catherine, Warne, Patricia H., Jiang, Ming, Saunders, Rebecca E., Melnick, Mary Ann, Gettinger, Scott, Walther, Zenta, Wurtz, Anna, Heynen, Guus J., Heideman, Daniëlle A.M., Gómez-Román, Javier, García-Castaño, Almudena, Gong, Yixuan, Ladanyi, Marc, Varmus, Harold, Bernards, René, Smit, Egbert F., Politi, Katerina, Downward, Julian
Médium: Artigo
Jazyk:Inglês
Vydáno: 2014
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011693/
https://ncbi.nlm.nih.gov/pubmed/24535670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0741
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky